SCHEMBL5495338

SCHEMBL5495338

CN1CCN(C(=O)Nc2ccc(Nc3ncc(-c4ccsc4)cn3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
FLT3 P36888 4/20 0.46
JAK2 O60674 3/20 0.46
CTSC P53634 1/20 0.45
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LCK P06239 2/20 0.41
MAPK14 Q16539 2/20 0.41
MAPT P10636 2/20 0.40
MAPKAPK2 P49137 1/20 0.40
NAMPT P43490 1/20 0.40
PDGFRB P09619 2/20 0.40
KIT P10721 2/20 0.40
PDGFRA P16234 2/20 0.40
ATM Q13315 1/20 0.39
BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5500638 0.88 SMN1; SMN2 (0.53) KDM4EFLT3JAK2SMN1; SMN2MAPT
SCHEMBL5495853 0.84 CYP3A4 (0.48) JAK2CTSCMAPTNAMPT
SCHEMBL5496170 0.84 MGLL (0.48) KDM4EJAK2CTSCALDH1A1SMN1; SMN2
SCHEMBL1734218 0.81 MAPT (0.61) SMN1; SMN2MAPTPDGFRB
SCHEMBL5501205 0.81 CTSC (0.62) JAK2CTSCSMN1; SMN2MAPT
SCHEMBL5499264 0.79 ABL1 (0.52) FLT3ABL1BCRLCKMAPK14
SCHEMBL5499872 0.78 THRB (0.50) MAPT
SCHEMBL5499974 0.77 KDM4E (0.49) KDM4EALDH1A1MAPT
SCHEMBL5496471 0.76 CTSC (0.49) KDM4ECTSCABL1ALDH1A1SMN1; SMN2
SCHEMBL14342350 0.76 CYP3A4 (0.47) CTSCMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US claimed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP claimed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO claimed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP disclosed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293484-A1 Thiophene Heteroaryl Amines TTK, CHEK2, ABL1 KDM4E 1354/4885FLT3 602/4885JAK2 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.